Emmett Investment Management LP Has $4.97 Million Position in CME Group Inc. $CME

Emmett Investment Management LP cut its holdings in shares of CME Group Inc. (NASDAQ:CME) by 20.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,960 shares of the financial services provider’s stock after selling 4,915 shares during the period. CME Group comprises approximately 4.5% of Emmett Investment Management LP’s portfolio, making the stock its 11th largest position. Emmett Investment Management LP’s holdings in CME Group were worth $4,972,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of CME. Price T Rowe Associates Inc. MD increased its holdings in CME Group by 89.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,280,785 shares of the financial services provider’s stock valued at $1,923,047,000 after purchasing an additional 3,921,278 shares during the period. GQG Partners LLC lifted its stake in shares of CME Group by 7,676.3% in the 1st quarter. GQG Partners LLC now owns 2,205,041 shares of the financial services provider’s stock valued at $584,975,000 after purchasing an additional 2,176,685 shares during the period. Wellington Management Group LLP boosted its holdings in shares of CME Group by 370.5% during the 1st quarter. Wellington Management Group LLP now owns 2,653,957 shares of the financial services provider’s stock worth $704,068,000 after buying an additional 2,089,935 shares in the last quarter. GAMMA Investing LLC boosted its stake in CME Group by 32,941.0% during the first quarter. GAMMA Investing LLC now owns 1,858,887 shares of the financial services provider’s stock worth $493,144,000 after acquiring an additional 1,853,261 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of CME Group during the 1st quarter worth about $218,842,000. Institutional investors and hedge funds own 87.75% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Piper Sandler lifted their price objective on shares of CME Group from $283.00 to $296.00 and gave the company an “overweight” rating in a report on Tuesday, July 15th. Morgan Stanley upped their price objective on shares of CME Group from $301.00 to $304.00 and gave the stock an “overweight” rating in a research report on Thursday, April 24th. UBS Group reiterated a “neutral” rating and issued a $305.00 price objective on shares of CME Group in a research note on Thursday, July 24th. Barclays set a $298.00 target price on shares of CME Group and gave the stock an “equal weight” rating in a research report on Thursday, July 24th. Finally, Erste Group Bank cut CME Group from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 24th. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $261.93.

Insider Transactions at CME Group

In related news, Director William R. Shepard acquired 256 shares of the stock in a transaction dated Wednesday, June 25th. The shares were purchased at an average price of $270.53 per share, for a total transaction of $69,255.68. Following the transaction, the director owned 258,196 shares in the company, valued at $69,849,763.88. This represents a 0.10% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Charles P. Carey sold 500 shares of the company’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $265.35, for a total transaction of $132,675.00. Following the completion of the transaction, the director owned 4,900 shares of the company’s stock, valued at $1,300,215. This trade represents a 9.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

CME Group Stock Up 0.4%

CME opened at $271.49 on Wednesday. CME Group Inc. has a one year low of $206.44 and a one year high of $290.79. The company has a fifty day moving average price of $275.67 and a 200-day moving average price of $267.85. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.02 and a quick ratio of 1.02. The firm has a market capitalization of $97.84 billion, a P/E ratio of 26.28, a price-to-earnings-growth ratio of 4.80 and a beta of 0.44.

CME Group (NASDAQ:CME) last issued its quarterly earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.91 by $0.05. The firm had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.68 billion. CME Group had a return on equity of 14.60% and a net margin of 58.48%.The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter last year, the company posted $2.56 EPS. Equities research analysts expect that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

CME Group Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 25th. Stockholders of record on Tuesday, September 9th will be issued a $1.25 dividend. The ex-dividend date of this dividend is Tuesday, September 9th. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.8%. CME Group’s dividend payout ratio is presently 48.40%.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.